Changes in tumor size by RECIST correlate with survival

Changes in tumor size by RECIST correlate with survival
RECIST categories used to quantify tumor changes during exposure to anticancer therapies correlate well with overall survival but reflect a more linear continuum without clear inflection points, according to a study published online June 11 in the Journal of Clinical Oncology.

(HealthDay) -- RECIST categories used to quantify tumor changes during exposure to anticancer therapies correlate well with overall survival (OS) but reflect a more linear continuum without clear inflection points, according to a study published online June 11 in the Journal of Clinical Oncology.

Rajul K. Jain, M.D., of the University of Texas MD Anderson Cancer Center in Houston, and colleagues studied the correlation between OS and response, as quantified by RECIST, in 570 participants of 24 phase I oncology trials conducted between October 2004 and May 2009.

The researchers found that 468 of the participants had quantifiable changes in tumor size. Change in tumor size during exposure to anticancer agents, as quantified by RECIST, correlated well with OS in a near-linear fashion without clear inflection points. Residual analyses were used to confirm the association.

"RECIST quantification of response correlates with survival, validating RECIST's use in phase I trials. However, the lack of apparent boundary values in the relationship between change in and OS demonstrates the arbitrary nature of the complete response/partial response/stable disease/ categories and questions emphasis placed on this categorization scheme," the authors write. "Describing tumor responses as a continuous variable may be more informative than reporting categoric responses when evaluating novel ."

One author disclosed a financial tie to Amgen.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Pancreatectomy OK without downstaging from therapy

May 25, 2012

(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published ...

Investigating better endpoints for immunotherapy trials

Sep 08, 2010

Cancer immunotherapy calls for revised clinical endpoints that differ from those used for chemotherapy, according to an article published online September 8 in The Journal of the National Cancer Institute.

High survival with surgery in low-risk neuroblastoma

Apr 25, 2012

(HealthDay) -- Surgery alone results in high five-year event-free and overall survival (EFS and OS) rates for patients with low-risk stage 2a and 2b neuroblastoma (NBL), according to research published online ...

Recommended for you

Same cancer, different time zone

6 hours ago

Just as no two people possess the same genetic makeup, a recent study has shown that no two single tumor cells in breast cancer patients have an identical genome.

Brazilian researchers identify RNA that regulates cell death

10 hours ago

Researchers from the University of São Paulo (USP) have identified an RNA known as INXS that, although containing no instructions for the production of a protein, modulates the action of an important gene in the process ...

User comments